Skip to main content

Lexiscan (regadenoson) Disease Interactions

There are 6 disease interactions with Lexiscan (regadenoson):


Regadenoson (applies to Lexiscan) MI

Major Potential Hazard, Moderate plausibility. Applicable conditions: Ischemic Heart Disease

The use of regadenoson has been associated with fatal and nonfatal myocardial infarction, ventricular arrhythmias, and cardiac arrest. Therapy with regadenoson should be avoided in patients with symptoms or signs of acute myocardial ischemia, such as unstable angina or cardiovascular instability as these patients may be at greater risk of serious cardiovascular reactions. Appropriate monitoring and equipment for resuscitation should be available before administering regadenoson. If serious reactions to regadenoson occur, consider the use of aminophylline, an adenosine antagonist, to shorten the duration of increased coronary blood flow induced by regadenoson administration.


Regadenoson (applies to Lexiscan) sinus/AV node dysfunction

Major Potential Hazard, High plausibility. Applicable conditions: Heart Block

The use of regadenoson is contraindicated in patients with second- or third- degree AV block, or with sinus node dysfunction in the absence of a functional artificial pacemaker. Adenosine receptor agonists, including regadenoson, can depress the SA and AV nodes and may cause first-, second- or third-degree AV block, or sinus bradycardia requiring intervention.


Regadenoson (applies to Lexiscan) arrhythmias

Moderate Potential Hazard, Moderate plausibility.

New-onset or recurrent atrial fibrillation with rapid ventricular response and atrial flutter, and cardiac arrest have occurred following regadenoson injection. Therapy with regadenoson should be administered cautiously in patients with cardiac conduction disorders.


Regadenoson (applies to Lexiscan) COPD/asthma

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Chronic Obstructive Pulmonary Disease

The use of regadenoson, as others adenosine receptor agonist may induce dyspnea, bronchoconstriction and respiratory compromise in patients with COPD or asthma. Appropriate bronchodilator therapy and resuscitative measures should be available prior to regadenoson administration.


Regadenoson (applies to Lexiscan) hypotension

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Valvular Heart Disease, Pericarditis, Cerebrovascular Insufficiency

The use of adenosine receptor agonists, including regadenoson, has been associated with arterial vasodilation and hypotension. The risk of serious hypotension may be higher in patients with autonomic dysfunction, hypovolemia, left main coronary artery stenosis, stenotic valvular heart disease, pericarditis or pericardial effusions, or stenotic carotid artery disease with cerebrovascular insufficiency.


Regadenoson (applies to Lexiscan) seizures

Moderate Potential Hazard, Moderate plausibility.

The use of regadenoson may lower the seizure threshold. New-onset or recurrence of convulsive seizures has occurred following regadenoson injection. Caution is recommended when using this agent in patients with or predisposition to seizure disorders.

Lexiscan (regadenoson) drug interactions

There are 6 drug interactions with Lexiscan (regadenoson)

Lexiscan (regadenoson) alcohol/food interactions

There are 2 alcohol/food interactions with Lexiscan (regadenoson)

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.